|
 |
DoxilThis page contains recent news articles, when available, and an overview of Doxil but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Doxil (when available) Doxorubicin is an antineoplastic in the anthracycline class. General properties of drugs in this class include: interaction with DNA in a variety of different ways including intercalation (squeezing between the base pairs), DNA strand breakage and inhibition with the enzyme topoisomerase II. Most of these compounds have been isolated from natural sources and antibiotics. However, they lack the specificity of the antimicrobial antibiotics and thus produce significant toxicity. The anthracyclines are among the most important antitumor drugs available. Doxorubicin is widely used for the treatment of several solid tumors while daunorubicin and idarubicin are used exclusively for the treatment of leukemia. Doxorubicin may also inhibit polymerase activity, affect regulation of gene expression, and produce free radical damage to DNA. Doxorubicin possesses an antitumor effect against a wide spectrum of tumors, either grafted or spontaneous. The anthracyclines are cell cycle-nonspecific. For the Treatment of Koposi's sarcome connected to AIDS Mechanism Of Action: Doxorubicin has antimitotic and cytotoxic activity through a number of proposed mechanisms of action: Doxorubicin forms complexes with DNA by intercalation between base pairs, and it inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, preventing the religation portion of the ligation-religation reaction that topoisomerase II catalyzes. News Articles on Doxorubicin Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite ... - Jan 1, 2010 Patients received any one of the following five thalidomide combination regimens: thalidomide, dexamethasone (Decadron), and Doxil (pegylated liposomal ... The Myeloma Beacon Increased immunogenicity of surviving tumor cells enables cooperation between ... - Dec 10, 2009 Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting ... 7thSpace Interactive (press release) Solano market mirrors nation, with a few exceptions - Jan 3, 2010 Eubanks Drive plant, where some 550 employees work, making products such as Sudafed, Nicoderm, and Doxil, an ovarian cancer medication. 7. ... TheReporter.com Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients ... - Dec 22, 2009 Results from another Phase 1 study that was presented at the ASH meeting show that Zolinza in combination with Doxil (pegylated liposomal doxorubicin) and ... The Myeloma Beacon FDA Approves Addition of Sustained Overall Survival Benefit to Label for ... - Jan 4, 2010 VELCADE plus DOXIL ® [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. ... dBusinessNews Boston (press release) SILENCE THERAPEUTICS PLC - Acquisition - Dec 16, 2009 ...oncology therapeutics including Doxil(R) (doxorubicin HCL liposome injection), PegIntron(R) (Peginterferon alfa-2b) and Vectibix(R) (panitumumab). ... Trading Markets (press release) Critical Outcome Technologies Inc. Reports Fiscal 2010 Second Quarter ... - Dec 10, 2009 ...and in combination with Doxil(R), had superior treatment results compared to Doxil(R) alone as measured by significant tumor growth inhibition in an ... FOXBusiness Zeltia gets final EU okay for Yondelis drug - Nov 2, 2009 N) Doxil for the treatment of ovarian cancer, but has so far failed to win a green light for the medicine in the United States. (Reporting by Tracy Rucinski ... Reuters Velcade-Doxil-Dexamethasone Combination Treatment Is Highly Effective In Newly ... - Oct 30, 2009 The second component of the VDD regimen, Doxil, blocks the process of DNA replication in cancerous cells, thus preventing them from multiplying. ... The Myeloma Beacon Phase 2 Clinical Trial Offers Positive Results For A Steroid-Free Multiple ... - Oct 26, 2009 Study participants were put on a four-week schedule of Velcade, Doxil and thalidomide. Their progress was monitored after each four-week interval for four ... The Myeloma Beacon Zeltia revenues up 15% boosted by Yondelis - Oct 30, 2009 ...regulators issued a positive recommendation on Yondelis to be used in combination with Johnson & Johnson's Doxil (doxorubicin) to treat ovarian cancer. ... Pharma Times Endocyte Presents Data On EC145 In Treatment Of Ovarian Cancer Before The ... - Oct 22, 2009 ...an international randomized study of EC145 in combination with Doxil®/Caelyx® versus Doxil®/Caelyx® alone in women with platinum-resistant ovarian ... Medical News Today (press release) Cancer Nanomedicine: Tiny Devices Make a Big Difference - Oct 27, 2009 In fact, several drugs have been approved by the FDA, including Doxil, an intravenous chemotherapy drug that employs liposomes - basically minute fatty ... DOTmed.com (press release) Endocyte Awarded Patent for Vitamin Receptor Binding Drug Delivery Conjugates - Oct 27, 2009 EC20 and EC145 are now being studied in an international randomized Phase 2b trial of EC145 in combination with Doxil® for the treatment of women with ... Reuters Millennium Initiates Phase II Trial for Diffuse Large B-Cell Lymphoma - Oct 21, 2009 VELCADE plus DOXIL® [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. ... Reuters Vacaville's ALZA up for sale - Oct 23, 2009 ...making such products as Sudafed, a popular cold medication; Nicoderm, a well-known nicotine patch; and Doxil, an ovarian cancer medication. ... Trading Markets (press release) J&J To Put California Manufacturing Plant Up For Sale - Oct 23, 2009 The deal also brought J&J the drugs Concerta for attention-deficit/hyperactivity disorder and cancer treatment Doxil. J&J's plan to sell the plant was ... NASDAQ Cancer drug developer Endocyte extends series C, reins in $26m - Oct 19, 2009 Endocyte Inc, a cancer drug discovery and development company, has closed a $26m extension of its series C financing round. The round included participation ... AltAssets å?µå·¢ç™Œè?¯Yondelis获欧洲上市许å?¯ - Nov 12, 2009 ...该è?¯ç›®å‰?与强生的Doxilï¼ˆé˜¿éœ‰ç´ ï¼‰ç»„å?ˆï¼Œäº§ç”Ÿäº†æ–°çš„适应è¯?。 Zeltiaå…¬å?¸è¡¨ç¤ºï¼Œè¯¥ç»„å?ˆè?¯å·²è¢«æ‰¹å‡†åœ¨åŒ…括挪å¨?ã€?冰岛以å?Šåˆ—支敦士登在内的27个欧盟国家上市。 ... 药通天下网 í•ì•”ì œ '욘ë?¸ë¦¬ìŠ¤' ìœ ëŸ½ì„ â€œìž˜ 나간다â€? - Nov 3, 2009 EU 집행위ì›?회는 2ì?¼ 욘ë?¸ë¦¬ìŠ¤ë¥¼ J&Jì?˜ ì•” ì¹˜ë£Œì œ 'ë?…실(Doxil)'ê³¼ ë³‘ìš©íˆ¬ì—¬í• ìˆ˜ 있ë?„ë¡? 승ì?¸í–ˆë‹¤. ì ¤í‹°ì•„ëŠ” ì?´ë²ˆ 승ì?¸ìœ¼ë¡œ 욘ë?¸ë¦¬ìŠ¤ì?˜ 매출액ì?´ 4ì–µ4000만달러ì—? ... 헬스코리아뉴스 Ð?анотрубки в медицине - Nov 4, 2009 прикрепленного к концу RGD цепи, но прÑ?мое Ñ?опоÑ?тавление полученных результатов Ñ? утвержденными Ñ?редÑ?твами (например, Ñ? Doxil) еще предÑ?тоит провеÑ?ти. ... Нанометр Approvata trabectedina in Europa - Nov 4, 2009 Il farmaco potrà ora essere utilizzato in combinazione con doxorubicina (Doxil) di Johnson & Johnson nei 27 paesi dell'Unione europea più Norvegia, ... Pharma Marketing Yondelis® recebe aprovação na UE para tratar cancro nos ovários - Nov 2, 2009 A Zeltia tem vindo a desenvolver o Yondelis® para utilizar em combinação com o Doxil® da Johnson & Johnson para tratamento do cancro nos ovários, ... POP - Portal de Oncologia Portugês מגמות-על בחקר המדע במ×?×” ×”-21: לקר×?ת סוף העשור הר×?שון - Oct 25, 2009 ...ליפוסומי×? המכילי×? ×?ת התרופה הציטוטוקסית ®Doxil, המצ×?תו של פרופ' יחזק×?ל ×‘×¨× ×”×•×œ×¥ (הפקולטה לרפו×?×”) וחבריו, × ×—×©×‘×™×? למערכת הר×?×©×•× ×” להולכת תרופות בשיטת ... הידען La CE autoriza el Yondelis de Zeltia para tratar el cáncer de ovario en la UE - Nov 2, 2009 ...la FDA (la agencia que aprueba los medicamentos en EE UU) no consideró "aprobable" la comercialización de Yondelis para su uso combinado con Doxil para ... El País (España) News: FRANCE ISRAËL - DOMINIQUE BOURRA A PRESENTE A TEL AVIV UN PLATEAU ... - Oct 30, 2009 Parmi les grand succès de Yissum, on trouve le médicament Exelon contre la maladie d'Alzheimer et la démence, le Doxil, un traitement contre le cancer des ... IsraelValley Zeltia jumps on ovarian cancer drug news - Aug 7, 2008 N) drug Doxil was statistically significantly better than using Doxil ... N) subsidiary that also makes existing treatment Doxil, will present the same ... Reuters US FDA Grants Full Approval To DOXIL(R) For Ovarian Cancer … - Feb 8, 2005 The US Food and Drug Administration (FDA) has granted full approval to DOXIL (doxorubicin HCl liposome injection) for the treatment of patients with ... Medical News Today - Medical News Today (press release) Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly ... - Dec 11, 2006 ORLANDO, Fla., Dec. 11 /PRNewswire-FirstCall/ -- Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) ... Free with registration - PR Newswire - AccessMyLibrary.com Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly ... - Dec 12, 2006 Researchers investigating the combination of DOXIL(R) (doxorubicin HCl liposome injection) and VELCADE(R) (bortezomib), the market leader in relapsed or ... Medical News Today - Medical News Today (press release) FDA approves VELCADE plus DOXIL combination for multiple myeloma - May 23, 2007 Ortho Biotech Products has announced the US Food and Drug Administration (FDA) has approved the use of DOXIL (doxorubicin HCl liposome injection) in ... News-Medical.net J&J recalling certain lots of drugs after theft - May 15, 2008 ...in Kentucky to a specialty distributor, was carrying the anemia treatment Procrit, the rheumatoid arthritis drug Remicade and the cancer medicine Doxil. ... Reuters US FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment … - May 21, 2007 BRIDGEWATER, NJ, May 21 /PRNewswire/ -- Ortho Biotech Products, LP, today announced the US Food and Drug Administration (FDA) has approved the use of ... RedOrbit US FDA grants full approval to DOXIL(R) for ovarian cancer progression... - Feb 9, 2005 ...(I-Newswire) - The US Food and Drug Administration ( FDA ) has granted full approval to DOXIL® ( doxorubicin HCl liposome injection ) for the treatment of ... i-newswire.com Ortho Biotech Files sNDA for DOXIL(R) for the Treatment of Advanced … - Sep 8, 2008 BRIDGEWATER, NJ, Sept. 8 /PRNewswire/ -- Ortho Biotech Products, LP today announced that the Company has submitted a supplemental new drug application ... RedOrbit Twelve DOXIL(R) Clinical Studies to be Presented at American Society... - Dec 7, 2007 ATLANTA, Dec. 7 /PRNewswire/ -- Ortho Biotech today announced that 12 clinical studies of DOXIL(R) (doxorubicin HCl pegylated liposome injection) will be ... Free with registration - PR Newswire - AccessMyLibrary.com Ortho Biotech Seeks FDA Approval For DOXIL(R) In Combination With … - Jan 23, 2007 Ortho Biotech Products, LP, today announced that the US Food and Drug Administration (FDA) has accepted an application for DOXIL(R) (doxorubicin HCl ... Medical News Today - Medical News Today (press release) Doxil Clinically Beneficial in Kaposi's Sarcoma - Nov 8, 2005 By FDA Advisory Committee, The data already submitted to FDA is sufficient to confirm clinical benefit of Johnson & Johnson's AIDS-related Kaposi's sarcoma ... RxPG NEWS Press Release: Two DOXIL(R) Studies to be Presented at American … - May 29, 2008 Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research … : Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with... - Jan 22, 2007 Ortho Biotech Seeks FDA Approval for DOXIL(R) in Combination with VELCADE(R) to Treat Relapsed/Refractory Multiple Myeloma. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Ortho Biotech Files sNDA for DOXIL(R) for the Treatment... - Sep 8, 2008 Ortho Biotech Files sNDA for DOXIL(R) for the Treatment of Advanced Breast Cancer. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Doxil (doxorubicin HCl liposome) Injection - Jan 28, 2005 New Indication: This supplemental new drug application provides for the use of Doxil (doxorubicin HCl liposome) Injection for the treatment of patients with ... Medscape Event Brief of Q4 2005 Telik, Inc. Earnings Conference Call - Part 1. - Feb 9, 2006 Doxil alone in second-line ovarian cancer. 1. Mature data from Phase 2 study of TELCYTA plus Doxil reported earlier remain strong, with regression-free ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Study Finds DOXIL(R) Combination Therapy Delays Disease Progression … - Dec 14, 2008 SAN ANTONIO, Dec. 14 /PRNewswire/ -- Results from a Phase 3 study showthat patients with metastatic breast cancer who were treated previously withan ... International Business Times Phase III Trial of YONDELIS(R) (Trabectedin) Initiated in Ovarian... - Apr 4, 2005 Liposomal doxorubicin (CAELYX(R)/DOXIL(R)) already has been approved for this ... As the combination of YONDELIS with CAELYX (DOXIL) also demonstrated ... Free with registration - PR Newswire Europe - AccessMyLibrary.com Event Brief of Q1 2006 Telik, Inc. Earnings Conference Call - Final. - May 4, 2006 Doxil in platinum resistant ovarian cancer. 5. TELK chose this as its next Phase III trial, because the data from its Phase II study of TELCYTA plus Doxil ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com CAELYX Delays Time To Metastatic Breast Cancer Progression - Jun 4, 2007 The product is marketed in the United States under the trade name DOXIL by Ortho Biotech ... DOXIL should be administered to patients with a history of ... emaxhealth.com Article: Doxil receives full approval.(PRODUCTS) - OB GYN News | … - Apr 1, 2005 Doxil receives full approval.(PRODUCTS) ... find OB GYN News articles. Doxil (doxorubicin HCl liposome injection) has been granted full approval for the ... Pay-Per-View - OB GYN News - HighBeam Research Bacteria enhance Doxil potency.(Tumours)(Brief article) | Article... - Dec 4, 2006 Bacteria enhance Doxil potency.(Tumours)(Brief article) ... find Chemistry and Industry articles. A novel way to attack tumours without damaging the ... Pay-Per-View - Chemistry and Industry - HighBeam Research New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection … - Jun 4, 2007 The VELCADE + DOXIL abstract was selected by the Best of the American Society of ... "The combination of VELCADE + DOXIL is highly active, with the time to ... Free with registration - PR Newswire - AccessMyLibrary.com FDA Safety Labeling Changes: Doxil, Concerta, and Fuzeon - Jan 12, 2005 Jan. 12, 2005 — The US Food and Drug Administration (FDA) approved in October 2004 revisions to safety labeling to advise healthcare professionals of the ... Medscape Bacteria enhance Doxil potency.(Tumours)(Brief article) - Dec 4, 2006 A novel way to attack tumours without damaging the surrounding tissue has been devised by a group of researchers using a combination of bacteria and ... $4.95 - Chemistry and Industry - ECNext … Release: US FDA Approves VELCADE(R) + DOXIL(R) Combination for … - May 21, 2007 US FDA Approves VELCADE(R) + DOXIL(R) Combination for Treatment of Relapsed/Refractory Multiple Myeloma. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Study Finds DOXIL(R) Combination Therapy Delays … - Dec 14, 2008 Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research FDA Safety Labeling Changes: Zometa, Doxil, Novamine - Mar 30, 2005 March 30, 2005 ( updated April 5, 2005) — The US Food and Drug Administration (FDA) approved in January revisions to safety labeling to advise healthcare ... Medscape … Release: Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in... - Jun 4, 2007 Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in Previously Treated Patients With Multiple Myeloma. from PR Newswire. Pay-Per-View - PR Newswire - HighBeam Research Press Release: Ortho Biotech Announces NDA Submission for … - Nov 20, 2008 If approved, trabectedin combined with DOXIL will provide a new, ... Trabectedin is being developed under a license from PharmaMar, and DOXIL is marketed by ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Interim Analysis Finds DOXIL(R)/VELCADE(R) … - Dec 11, 2006 Interim Analysis Finds DOXIL(R)/VELCADE(R) Combination Significantly Prolongs Time to Progression in Previously Treated Multiple Myeloma Patients. from PR ... Pay-Per-View - PR Newswire - HighBeam Research FDA Approvals: Doxil, Lower-Dose Duragesic, Eloxatin - Feb 10, 2005 Feb. 10, 2005 — The US Food and Drug Administration (FDA) has approved a revised indication for doxorubicin HCl liposome injection, allowing its use in ... Medscape Doxil.(drug approval)(Brief Article) - Apr 1, 2005 FDA granted full approval for doxorubicin liposome injection (Doxil, Tibotec Therapeutics) in the treatment of patients with ovarian cancer whose disease ... Free with registration - Managed Healthcare Executive - AccessMyLibrary.com Doxorubicin-Loaded Dendrimer Offers Hope for Colon CA - Nov 14, 2006 The mice were injected with colon cancer cells, and several days later with doxorubicin, doxorubicin-dendrimer or Doxil. Though the latter two cured the ... Medgadget.com Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 … - Mar 10, 2008 Both platinum-resistant and Doxil-resistant patients in the Phase 2 clinical trial have responded to SNS-595 therapy. "Recurrence rates among ovarian cancer ... Lifescience-online Ortho Biotech seeks OK for Doxil/Velcade combo.(Ortho Biotech... - Jan 29, 2007 Ortho Biotech Products says that the US Food and Drug Administration has accepted an application for Doxil (doxorubicin HCl liposome injection) as ... $4.95 - Pharma Marketletter - ECNext DRUG COMBINATION SLOWS PROGRESSION OF TREATMENT- … - Dec 11, 2006 Doxil is a liposmal version of an older drug, doxorubicin, which means the ... Orlowski and others first found that doxorubicin and Doxil may complement ... Pay-Per-View - US Fed News - Factiva, from Dow Jones Doxil request. - Sep 29, 2008 Johnson & Johnson is seeking to expand the use of Doxil, approved as a backup treatment for ovarian cancer. J&J has asked the Food and Drug Administration ... $9.94 - Chain Drug Review - Alacra Store … : US FDA Grants Full Approval to DOXIL(R) Following Submission of … - Feb 7, 2005 US FDA Grants Full Approval to DOXIL(R) Following Submission of Phase III Data; - Product Label Updated to Include Ovarian Cancer Progression, Survival and ... Pay-Per-View - PR Newswire - HighBeam Research Doxil.(Recently Approved) - Jul 1, 2007 Bridgewater, NJ-based Ortho Biotech Products LP's Doxil (doxorubicin HCl liposome injection) has been cleared for use in combination with London-based ... $4.95 - Pharmaceutical Representative - ECNext Article: FDA approves Ortho's Doxil for treating cancer patients.(RXs)... - Feb 28, 2005 FDA approves Ortho's Doxil for treating cancer patients.(RXs)(Food and Drug Administration)(Brief Article) ... find Chain Drug Review articles. Pay-Per-View - Chain Drug Review - HighBeam Research AACR: Intraductal Drug Delivery Evaluated for Breast Cancer - Apr 18, 2008 Intraductal administration of carboplatin and pegylated liposomal doxorubicin (Doxil) resulted in epithelial cell loss within the ducts, consistent with ... MedPage Today Event Brief of Q3 2005 Telik, Inc. Earnings Conference Call - Part 1. - Nov 8, 2005 244 patients are being randomized to receive either the combination of Carboplatin and TELCYTA or the comparative drug, Doxil. 1. Doxil was chosen because ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Halozyme Therapeutics reports positive pre-clinical results of enzyme... - Jul 22, 2008 ...with the chemotherapeutic drugs, docetaxel (Taxotere), or liposomal doxorubicin (Doxil), resulted in a substantial increase in anti-tumor activity. ... $9.94 - M2 Europharma - Alacra Store How to take Sorafenib from Consumer Reports Health. - Jan 8, 2007 ...carbamazepine (Equetro, Tegretol), cyclophosphamide (Cytoxan, Neosar), dexamethasone, doxorubicin (Doxil, Adriamycin), efavirenz (Sustiva), ifosfamide, ... consumerreports.org Doxil receives full approval.(Products)(Brief Article) | Article from... - Jun 1, 2005 Doxil receives full approval.(Products)(Brief Article) ... find Family Practice News articles. Doxil (doxorubicin HCl liposome injection) has been granted ... Pay-Per-View - Family Practice News - HighBeam Research USA biotech: Telik cancer study misses mark - Oct 31, 2008 That same trial did not have a Doxil plus Telcyta arm. The Phase III trial known as Assist-5 had a target enrollment of 244 patients, but only 125 were ... $34.00 - EIU Country Analysis - Alacra Store Doxil: Doxorubicin liposome injection.(New indication)(Drug overview) - Jul 1, 2007 Anthracycline topoisomerase inhibitor approved in combination with bortezomib for the treatment of multiple myeloma Doxorubicin is thought to work by ... $4.95 - Formulary - ECNext Article: Doxil receives full approval.(PRODUCTS)(Brief Article) -... - Apr 1, 2005 Doxil receives full approval.(PRODUCTS)(Brief Article) ... find Internal Medicine News articles. Doxil (doxorubicin HCl liposome injection) has been granted ... Pay-Per-View - Internal Medicine News - HighBeam Research … US approval for Ortho Biotech's Doxil.(Ortho Biotech Products... - Feb 14, 2005 The US Food and Drug Adminstration has granted full approval to Doxil (doxorubicin HCl liposome injection), a treatment for ovarian cancer that has ... $4.95 - Pharma Marketletter - ECNext Women Touched By Ovarian Cancer Saluted at 'Celebrating Survivors' … - Sep 20, 2005 DOXIL is an advanced form of doxorubicin, a drug commonly used to treat cancer. DOXIL is surrounded by a coating that allows it to stay in the blood longer ... RedOrbit FDA Approves Velcade® for Second Line Treatment of Myeloma - Mar 25, 2005 Velcade® has also been evaluated in combination with Doxil® with promising results. The results of a large phase II multicenter trial involving 202 patients ... Cancer Consultants Delivering on Nano's Promise - Oct 9, 2006 The fact that Doxil was a reformulation of an earlier drug, ... This carrier allows Doxil to evade the body's immune system, thus increasing the time the ... Drug Discovery & Development Ovarian Cancer; US FDA grants approval to ovarian cancer treatment … - Mar 7, 2005 Doxil, marketed in the United States by Tibotec Therapeutics, ... As a result of the full approval, the product label for Doxil has been updated to include ... Pay-Per-View - Clinical Trials Week - Factiva, from Dow Jones Ovarian Cancer; US FDA grants approval to ovarian cancer treatment … - Mar 13, 2005 Doxil, marketed in the United States by Tibotec Therapeutics, ... As a result of the full approval, the product label for Doxil has been updated to include ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones Ovarian Cancer; US FDA grants approval to ovarian cancer treatment … - Mar 8, 2005 Doxil, marketed in the United States by Tibotec Therapeutics, ... As a result of the full approval, the product label for Doxil has been updated to include ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones … Foundation Reports New Drug Combination - Velcade(R) Plus Doxil(R)... - May 21, 2007 The combination of Doxil(R) with Velcade(R) provides nearly a three month ... Doxil is a specially (liposomal) formulated version of the chemotherapy agent ... Pay-Per-View - PR Newswire - HighBeam Research 'Money is not the most important thing in this business': It takes a ... - Oct 4, 2006 Yechezkel Barenholz had to endure until Doxil became Israel's only commercial cancer drug. ... find Globes (Tel Aviv, Israel) articles. Pay-Per-View - Globes - HighBeam Research Zeltia demuestra el éxito de Yondelis contra el cáncer de ovario y... - Sep 16, 2008 ...han demostrado que las mujeres que recibieron una combinación de Yondelis y quimioterapia conjuntamente con Doxil (el antitumoral de referencia en esta ... La Voz de Galicia Fat chance - Dec 8, 2007 DOXIL, THE liposome-based medication modelled on the drug doxorubicin that ... The Doxil liposomes were designed to have a natural ability to target cancer. ... Jerusalem Post Press Release: Telik Announces Top-Line Results From Assist-5 Trial... - Oct 29, 2008 The results included: -- TELCYTA plus carboplatin in platinum refractory or ... trial, to evaluate the combination of TELCYTA plus carboplatin versus Doxil ... Pay-Per-View - PR Newswire - HighBeam Research Drugs and vaccines by 'special delivery' - Dec 9, 2007 As Doxil, given by infusion, will lose its patent protection in two or ... Doxil doesn't hurt the immune system, so you can start immunotherapy and get ... Pay-Per-View - Jerusalem Post - ProQuest Archiver Phase III Trial of YONDELIS(R) (Trabectedin) Initiated in Ovarian... - Mar 20, 2005 Liposomal doxorubicin (CAELYX(R)/DOXIL(R)) already has been approved for this ... As the combination of YONDELIS with CAELYX (DOXIL) also demonstrated ... prnewswire.co.uk COMUNICADO: Resultados positivos de tres nuevos estudios … - Jun 5, 2006 DOXIL(R) (doxorubicin HCI liposome injection) se comercializa en Estados Unidos por Tibotec Therapeutics, una división de Ortho Biotech Products, LP., ... elEconomista.es PharmaMar pide comercialización de Yondelis para cáncer de ovario … - Dec 4, 2008 Medicamentos (EMEA) la comercialización de Yondelis, administrado en combinación con Doxil/Caelyx para el tratamiento de cáncer de ovario refractario. ... ADN.es PharmaMar pide comercialización de Yondelis para cáncer de ovario … - Apr 12, 2008 Medicamentos (EMEA) la comercialización de Yondelis, administrado en combinación con Doxil/Caelyx para el tratamiento de cáncer de ovario refractario. ... Finanzas.com … a FDA aprobar el uso de 'Yondelis' (PharmaMar) con 'Doxil' en... - Nov 20, 2008 Además, los eventos adversos asociados comúnmente a 'Doxil', como el sÃndrome pie-mano(HFS) y estomatitis, se produjo en un menor número de pacientes que ... ecodiario An Update of Treatments for Multiple Myeloma: Results from the 2006 … - Dec 9, 2006 The Greek Myeloma study group compared VAD-Doxil® (pegylated liposomal doxorubicin) to VAD-Doxil +Thalomid as primary induction therapy. ... Cancer Consultants Telik Announces Initiation Of New TELCYTA Phase 3 Clinical Trial And ... - May 3, 2006 ASSIST-5 is based on the positive results previously reported from a multicenter Phase 2 study of the combination of TELCYTA plus Doxil in platinum ... Medical News Today - Medical News Today (press release) Piden a EEUU permiso para usar "Yondelis" e "Doxil" en cancro ovárico - Nov 21, 2008 A compañÃa farmacéutica Ortho Biotech Products, filial de Johnson&Johnson, propuxo hoxe á Axencia Americana do Medicamento (FDA, nas súas siglas en inglés) ... El Correo Gallego СпиÑ?ок показаний противоопухолевого препарата Doxil® может уве - Jan 24, 2007 Ð?мериканÑ?каÑ? компаниÑ? Ortho Biotech Products, LP Ñ?ообщила о подаче в FDA заÑ?влениÑ? на региÑ?трацию инъекционного препарата Doxil® (Doxorubicin HCl), ... ФармацевтичеÑ?кий веÑ?тник EDITED BRIEF - May 8, 2008 Febrile neutropenia, a major hematologic toxicity occurred only on Doxil arm. 5. Non-hematologic toxicity were more common on Doxil arm as expected. ... $54.00 - Thomson StreetEvents - Alacra Store Invertia.com - mercados,finanzas,economÃa, fondos y cotizaciones - Apr 4, 2005 ..."Dado que la combinación de Yondelis con Caelyx (Doxil) también demostró actividad y tolerabilidad en un estudio previo, la base teórica del estudio es que ... Invertia Pegylated Liposomal Doxorubicin (PLD): Enhanced skin toxicity in... - Sep 12, 2008 Pegylated liposomal doxorubicin (PLD; Doxil; Caelyx) is widely used for the ... Due to this reaction, the fourth dose of Doxil was held and she was re-dosed ... ecancermedicalscience Antibody Targeting Boosts Liposomal Drug Anticancer Activity - Dec 9, 2007 Researchers at Northeastern University have improved the tumor-killing activity of liposomal doxorubicin, known as Doxilâ„¢, by attaching a monoclonal ... Nanotechwire.com YONDELIS(TM) (trabectedin) Phase II Trials Demonstrate Activity in … - May 16, 2005 A Phase I trial of 30 heavily pre-treated patients was conducted to study the combination of YONDELIS and PLD, known as CAELYX(R) in Europe, and DOXIL(R) ... Free with registration - PR Newswire Europe - AccessMyLibrary.com "Yondelis" reduce nun 15% o risco de morte polo cancro de ovario - Sep 16, 2008 ...destacou que o estudo Oval-301 -desenvolvido por Pharmamar e Johnson & Johnson Pharmaceutical Research que comercializa a quimioterapia Doxil- confirman ... El Correo Gallego ALICIA'S STORY Goodbye, interferon, hello, chemo -- new step in the … - Feb 2, 2007 First Dr. Jahan mentioned Doxil, which contains Adriamycin. "Adriamycin?" I said. "The chemo drug?" A drug my mom, who died of non-Hodgkin's lymphoma, ... San Francisco Chronicle Press Release: IMPAX Receives Final FDA Approval. - M2 Presswire | … - Nov 10, 2006 M2 Presswire; July 15, 2007 ; 700+ words ... ... ethinyl estradiol), a low-dose oral contraceptive; DOXIL (doxorubicin HCI liposome injection), ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Mylan Receives Final FDA Approval for Oxybutynin … - Nov 13, 2006 M2 Presswire; July 15, 2007 ; 700+ words ... ... dose oral contraceptive; DOXIL (doxorubicin HCI liposome injection), a cancer treatment; ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Telik Announces Initiation of New TELCYTA Phase 3 … - May 2, 2006 ASSIST-5 is based on the positive results previously reported from a multicenter Phase 2 study of the combination of TELCYTA plus Doxil in platinum ... Pay-Per-View - PR Newswire - HighBeam Research Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 4, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased ... "Doxil minimally affected the expression levels of p53, whereas other ... Pay-Per-View - Proteomics Weekly - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 4, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased ... "Doxil minimally affected the expression levels of p53, whereas other ... Pay-Per-View - Clinical Oncology Week - Factiva, from Dow Jones Clinical Trials; Clinical trial results of drug in prostate, ovarian,... - Jun 21, 2005 A phase 1 trial of 30 heavily pretreated patients was conducted to study the combination of Yondelis and PLD, known as Caelyx in Europe, and Doxil ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 5, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased ... "Doxil minimally affected the expression levels of p53, whereas other ... Pay-Per-View - Science Letter - Factiva, from Dow Jones Anti-Infectives; Liposomal doxorubicin formulation has reduced … - Apr 5, 2005 ..."Endothelial viability did not change significantly with doxil, but was decreased ... "Doxil minimally affected the expression levels of p53, whereas other ... Pay-Per-View - Cancer Weekly - Factiva, from Dow Jones Ortho Biotech, LP And Centocor, Inc. Alert Authorized Distributors... - May 15, 2008 17314-9600-2 DOXIL(R) (doxorubicin HCl 0715423 02/2009 liposome injection) 50mg in 25mL (2mg/mL) single use vial 57894-0300-1 Cartons containing one (1) ... RedOrbit New Combo Treatment for Ovarian Cancer - Nov 4, 2005 For these women, DOXIL is currently the standard of care for platinum-resistant ... Dr. Duska says both DOXIL and TELCYTA are well-tolerated treatments. ... Ivanhoe Broadcast News Novel approach to detoxifying cancer drugs - Nov 7, 2006 ..."The dendrimer is as good as Doxil. Doxil is a lot less toxic than doxorubicin, and I think the dendrimer will be a lot less toxic for many of the same ... PhysOrg.com Drug Combination Slows Progression Of Treatment Resistant Bone … - Dec 16, 2006 Doxil is a liposmal version of an older drug, doxorubicin, which means the ... Orlowski and others first found that doxorubicin and Doxil may complement ... Medical News Today - Medical News Today (press release) Ortho Biotech Files sNDA for Breast Cancer Drug - Sep 9, 2008 Ortho Biotech Products, a biopharmaceutical company, has submitted a supplemental new drug application to the FDA for the combination of Doxil and Taxotere ... RedOrbit Betting on Nanotech Therapies - Sep 12, 2007 A milestone came in 1995 with the US approval of Doxil, ... Because Doxil liposomes are so small -- about 100 nanometers in diameter -- and able to ... Subscription - Wall Street Journal Online - Dow Jones & Company Ovarian Cancer; Telik initiates phase 3 Telcyta trial, updates status... - May 29, 2006 ASSIST-5 is based on the positive results previously reported from a multicenter phase 2 study of the combination of Telcyta plus Doxil in platinum ... Pay-Per-View - OBGYN & Reproduction Week - Factiva, from Dow Jones Straits Gold Pty Ltd withdraws offer for Goldminco Corp-Tenements(2) ... - Sep 2, 2008 Accounts gained: Alza Pharmaceuticals: Doxil; IDEC Pharmaceuticals Corp. ... Ortho Biotech Inc.: Doxil; Ortho-McNeil Pharmaceuticals Inc.: Ditropan XL, ... Pay-Per-View - deals - Alacra Store Press Release: Millennium and Ortho Biotech Enter into US Co- … - Oct 26, 2006 Article: Ortho Biotech Seeks FDA Approval for DOXIL(R) in ... PR Newswire; January 22, ... Article: Ortho Biotech Files sNDA for DOXIL(R) for the ... ... Pay-Per-View - PR Newswire - HighBeam Research Zeltia drug delays progression of ovarian cancer - Sep 15, 2008 Monk said the results showed those women given a combination of Yondelis and Johnson & Johnson's chemotherapy drug Doxil had no progression of their cancer ... Reuters Zeltia Group - May 6, 2006 ...(1) DOXIL(r) (doxorubicin HCI liposome injection) is marketed in the United States by Tibotec Therapeutics, a Division of Ortho Biotech Products, LP, ... presseportal.ch Q4 2006 Telik, Inc. Earnings Conference Call - Part 1. - Feb 22, 2007 As you recall, ASSIST-5 is an add-on trial that is evaluating the combination of TELCYTA plus Doxil versus Doxil in 2nd-line Platinum Refractory or ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Event Brief of Q2 2006 Telik, Inc. Earnings Conference Call - Final. - Aug 3, 2006 ...s ASSIST-3 trail using the combination of TELCYTA and carboplatin and the ASSIST-5 trial using the combination of TELCYTA and Doxil in platinum resistant ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Brand Names/Synonyms: Doxil is also known by the following brand names and/or synonymsADM; Adriablastin; Adriamycin; Adriamycin Pfs; Adriamycin Rdf; Adriamycin Semiquinone; Adriblastin; Adriblastina; CCRIS 739; Caelyx;; DM2; Doxil; Doxo; Doxorubicin; Doxorubicin Hcl; Doxorubicin Hydrochloride; Doxorubicin [Usan:Ban:Inn]; Doxorubicina [Inn-Spanish]; Doxorubicine [Inn-French]; Doxorubicinum [Inn-Latin]; FI 106; FI-106; HSDB 3070; Rdf Rubex; Rubex Drug Category: Doxil is categorized under the following by the FDA: Antibiotics; Antineoplastic Agents; ATC:L01DB01 Dosage Forms: POWDER FOR SOLUTION Absorption: Not Available Interactions: [an error occurred while processing this directive] Chemical IUPAC Name: 10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl)oxy-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |